2011

Allergan, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, Novo, and Sanofi-Aventis filed a 'citizen petition' with the FDA, urging the agency to 'establish comprehensive, clear and binding regulations to guide the industry' in communicating off-label drug information to physicians and payers. Although the words 'Internet' and 'Social Media' are not mentioned in the petition, it is likely to hold up social media guidelines regarding 'unsolicited requests' that were promised as the first in a series of FDA guidelines.

Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?

Welcome to Volume 10, Issue #17 (10 NOVEMBER 2011) of Pharma Marketing News.

This article focuses on Adobe Connect for eDetailing, a specific collaboration between Adobe and ConnectSolutions, a leading provider of private cloud deployments of web conferencing and collaboration solutions.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

A summary of the highly anticipated 2011 results of Kantar Health's annual Stakeholder Effectiveness survey, which revealed that over two-thirds of respondents from leading companies in the pharmaceutical sector think that customer retention is a key performance measure.

Are we witnessing an exodus of social media

How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.

Welcome to Volume 10, Issue #8 (28 APRIL 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #16 (27 OCTOBER 2011) of Pharma Marketing News.